CompletedEUCTR 2012-003699-37
Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesAnxiety
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Czechia · Finland and 4 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 510
- Sponsor
- Institut de Recherches Internationales Servier
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Czechia, Finland, Germany, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2012-003699-37
- Official title
Show the full official title
Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in...
Get this study by email
Recruitment & locations
CompletedCzechia · Finland · Germany
3 more locations
- Hungary
- Poland
- Slovakia
Questions about this study
Who is behind this study?
The study sponsor is Institut de Recherches Internationales Servier, a research institute.
Want to explore more studies?
Explore studiesRelated studies
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD)